Role of programmed death ligands in effective T‑cell interactions in extranodal natural killer/T‑cell lymphoma

  • Authors:
    • Lijuan Han
    • Feifei Liu
    • Ruping Li
    • Zhaoming Li
    • Xinfeng Chen
    • Zhiyuan Zhou
    • Xudong Zhang
    • Tengpeng Hu
    • Yi Zhang
    • Ken Young
    • Suke Sun
    • Jianguo Wen
    • Mingzhi Zhang
  • View Affiliations

  • Published online on: July 17, 2014
  • Pages: 1461-1469
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Extranodal natural killer/T‑cell lymphoma (ENKL) is marked by a profound cellular immune deficiency that may influence the capacity of T cells to extract an efficient antitumor immune response. It has been confirmed that the B7‑CD28 pathway may promote tumor immune evasion by providing a negative regulatory signal. The current study analyzed the expression of programmed death 1 (PD‑1)/programmed death ligand (PD‑L) in ENKL cell lines and tissues. The functional studies were performed to analyze the functional activity of PD‑L1 interacting with effective T cells in ENKL. PD‑L1 and PD‑L2 mRNA levels in ENKL cell lines were markedly upregulated compared with those in normal natural killer cells. The proteins constitutively expressed in the 30 ENKL specimens were significantly higher than in the 20 rhinitis specimens. In addition, PD‑L1 and PD‑L2 expression were found to closely correlate with certain clinical histopathological parameters. Furthermore, the count of PD‑1+ tumor‑infiltrating T lymphocytes was found to negatively correlate with the expression of PD‑L1 and PD‑L2. The PD‑1 expression in the CD4+ and CD8+ T‑cell subsets of 20 ENKL patients prior to therapy were significantly higher than that of the 10 healthy volunteers. In the functional studies, the cytokines (interleukin‑2 and interferon‑γ) secreted by CD8+ T cells were inhibited by PD‑L1 expression in SNK‑6 cells and this was restored with the presence of the PD‑L1 blocking antibody. However no direct effect of PD‑L1 was identified on CD8+ T‑cell apoptosis and CD8+ T‑cell cytotoxicity, as assessed by the proliferation of SNK‑6 cells in the presence or absence of the neutralizing anti‑PD‑L1 antibody. The results of the current study revealed that PD‑Ls and PD‑1 are aberrantly expressed in ENKL and, furthermore, PD‑L1 expression in SNK‑6 cells was found to inhibit the activity of CD8+ T‑cell cytokine secretion. This indicated that the PD‑Ls may prevent effective antitumor immunity in vivo by interacting with tumor T cells, which provides important evidence to delineate the cellular immune deficiency mechanism in ENKL. Therefore, PD‑1/PD‑Ls are predicted to become novel targets for ENKL immunotherapy.



Harabuchi Y, Takahara M, Kishibe K, et al: Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features. Int J Clin Oncol. 14:181–190. 2009.


Jaffe ES: The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009:523–531. 2009.


Mao Y, Zhang DW, Zhu H, et al: LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL). Diag Pathol. 7:1782012.


Roma E and Smith AG: Epidemiology of lymphoma. Histopathology. 58:4–14. 2011.


Suzuki R: NK/T-Cell Lymphomas: pathobiology, prognosis and treatment paradigm. Curr Oncol Rep. 14:395–402. 2012.


Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 4:336–347. 2004.


Fife BT, Panken KE, Eagar TN, et al: Interractions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 10:1185–1192. 2009.


Atanackovic D, Luetkens T and Kröger N: Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia. Oct 23–2013.(Epub ahead of print).


Zitvogel L and Kroemer G: Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 1:1223–1225. 2012.


Iwamura K, Kato T, Miyahara Y, et al: siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Ther. 19:959–966. 2012.


Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012.


Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012.


Chen BJ, Chapuy B, Ouyang J, et al: PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 19:3462–3473. 2013.


Beahrs OH, Henson DE and Hutter RVP: Handbook for staging of cancer, from the manual for staging of cancer. 4th ed. American joint committee on cancer (AJCC). JB Lippincott Co; 257. pp. 1992


Taube JM, Anders RA, Young GD, et al: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 4:127ra372012.


Li Y, Wang J, Li C and Ke XY: Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk Lymph. 53:2015–2023. 2012.


Greaves P and Gribben JG: The role of B7 family molecules in hematological malignancy. Blood. 121:734–744. 2013.


Rozali EN, Hato SV, Robinson BW, et al: Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012:6563402012.


Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895. 1992.


Loke P and Allison JP: PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA. 100:5336–5341. 2003.


Andorsky DJ, Yamada RE, Said J, et al: Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 17:4232–4244. 2011.


Yamamoto R, Nishikori M, Kitawaki T, et al: PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 111:3220–3224. 2008.


Brusa D, Serra S, Coscia M, et al: The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 98:953–963. 2013.


Nomi T, Sho M, Akahori T, et al: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 13:2151–2157. 2007.


Ohigashi Y, Sho M, Yamada Y, et al: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 11:2947–2953. 2005.


Grzywnowicz M, Zaleska J, Mertens D, et al: Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One. 7:e351782012.


Green MR, Rodig S, Juszczynski P, et al: Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 18:1611–1618. 2012.


Takahashi H, Tomita N, Sakata S, et al: Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era. Eur J Haematol. 90:286–290. 2013.


Ohmatsu H, Suqaya M, Fujita H, et al: Primary cutaneous follicular helper T-cell lymphoma treated with allogeneic bone marrow transplantation: immunohistochemical comparison with angioimmunoblastic T-cell lymphoma. Acta Derm Venereol. Jan;2014.(Epub ahead of print).


Chen L: B7-H1 connection of innate and adaptive immunity against tumor dormancy. Blood. 105:2242–2243. 2005.


Abiko A, Mandai M, Hamanishi J, et al: PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res. 19:1363–1374. 2013.


Yamamoto R, Nishikori M, Tashima M, et al: B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci. 100:2093–2100. 2009.


Küppers R: The biology of Hodgkin’s lymphoma. Nat Rev Cancer. 9:15–27. 2009.

Related Articles

Journal Cover

October 2014
Volume 8 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
Han, L., Liu, F., Li, R., Li, Z., Chen, X., Zhou, Z. ... Zhang, M. (2014). Role of programmed death ligands in effective T‑cell interactions in extranodal natural killer/T‑cell lymphoma. Oncology Letters, 8, 1461-1469.
Han, L., Liu, F., Li, R., Li, Z., Chen, X., Zhou, Z., Zhang, X., Hu, T., Zhang, Y., Young, K., Sun, S., Wen, J., Zhang, M."Role of programmed death ligands in effective T‑cell interactions in extranodal natural killer/T‑cell lymphoma". Oncology Letters 8.4 (2014): 1461-1469.
Han, L., Liu, F., Li, R., Li, Z., Chen, X., Zhou, Z., Zhang, X., Hu, T., Zhang, Y., Young, K., Sun, S., Wen, J., Zhang, M."Role of programmed death ligands in effective T‑cell interactions in extranodal natural killer/T‑cell lymphoma". Oncology Letters 8, no. 4 (2014): 1461-1469.